Instil Bio Announces Resumption of Clinical Trial of CoStAR-TIL Candidate ITIL-306 in Lung, Ovarian, and Renal Cancer

January 9, 2023

https://www.globenewswire.com/news-release/2023/01/09/2585021/0/en/Instil-Bio-Announces-Resumption-of-Clinical-Trial-of-CoStAR-TIL-Candidate-ITIL-306-in-Lung-Ovarian-and-Renal-Cancer.html

Phase 1 trial of ITIL-306 in NSCLC, ovarian, and RCC re-opened to enrollment after voluntary pause

Initial data readout for ITIL-306 expected in 2023

Read more at globenewswire.com

Related news for (TIL)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.